Key facts
- Creyon’s last known valuation is $72.2M (Mar 2022).
- It has raised $45.5M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Lux Capital, Alexandria Venture Investments, Casdin Capital, DCVC Bio, Biobrit — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Creyon
- ·The full record, as it builds
Funding rounds
No funding rounds for Creyon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Creyon
Developer of drugs designed to engineer RNA-based medicines and their components. The company creates proprietary, purpose-built datasets that inform powerful machine learning models, identifying the design rules and engineering principles for safe and effective OBMs, enabling the healthcare sector to save costs for new medicines.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2019
- Employees
- 46
- Website
- creyon.com/
- Ownership
- Privately Held (backing)
Creyon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Creyon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Creyon in its N-PORT filings yet. We sweep new filings monthly.